Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3702 |
Name | cervical adenocarcinoma |
Definition | A cervix carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer cervix carcinoma cervical adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 amp FGFR2 mut | Debio 1347 | cervical adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01101451 | Phase III | Cisplatin | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | Active, not recruiting | USA | 2 |
NCT02257528 | Phase II | Nivolumab | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | Active, not recruiting | USA | 0 |
NCT02348398 | Phase II | Pazopanib + Topotecan | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | Withdrawn | 0 | |
NCT02466971 | Phase III | Cisplatin Cisplatin + Triapine | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Active, not recruiting | USA | CAN | 1 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Active, not recruiting | USA | ITA | GBR | ESP | 2 |
NCT02595879 | Phase I | Cisplatin + Triapine | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | Active, not recruiting | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02853604 | Phase III | ADXS11-001 | Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) | Terminated | USA | ESP | CAN | 11 |
NCT03108495 | Phase II | LN-145 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 2 |
NCT03367871 | Phase II | Cisplatin + Paclitaxel + Pembrolizumab | Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer | Terminated | USA | 0 |
NCT03438396 | Phase II | Tisotumab vedotin-tftv | A Trial of Tisotumab Vedotin in Cervical Cancer | Completed | USA | ITA | ESP | DEU | BEL | 3 |
NCT03495882 | Phase Ib/II | Balstilimab + Zalifrelimab | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | Completed | USA | ESP | AUS | 6 |
NCT03556839 | Phase III | Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 3 |
NCT03612791 | Phase II | Cisplatin Atezolizumab + Cisplatin | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) | Recruiting | FRA | 0 |
NCT03635567 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 12 |
NCT03644342 | Phase Ib/II | Niraparib | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) | Suspended | USA | 0 |
NCT03738228 | Phase I | Atezolizumab + Cisplatin | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | Active, not recruiting | USA | 0 |
NCT03786081 | Phase Ib/II | Bevacizumab + Tisotumab vedotin-tftv Carboplatin + Tisotumab vedotin-tftv Pembrolizumab + Tisotumab vedotin-tftv | Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Active, not recruiting | USA | ITA | GBR | ESP | BEL | 5 |
NCT03830866 | Phase III | Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) | Completed | USA | 14 |
NCT03833479 | Phase II | Dostarlimab-gxly | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) (ATOMICC) | Active, not recruiting | ESP | 1 |
NCT03894215 | Phase II | Balstilimab Balstilimab + Zalifrelimab | Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Active, not recruiting | USA | 6 |
NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Unknown status | GBR | 0 |
NCT04205799 | Phase II | Cabozantinib | Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) | Completed | FRA | 0 |
NCT04221945 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 20 |
NCT04230954 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | Terminated | USA | 0 |
NCT04238988 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3) | Unknown status | ITA | 0 |
NCT04246489 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | Completed | USA | FRA | ESP | BEL | AUS | 7 |
NCT04300647 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 10 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Recruiting | USA | 9 |
NCT04405349 | Phase II | Atezolizumab + VB10.16 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | Active, not recruiting | DEU | BEL | 4 |
NCT04487587 | Phase II | Cediranib + Olaparib | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) | Unknown status | GBR | 0 |
NCT04551950 | Phase I | Bevacizumab + Bintrafusp alfa + Carboplatin + Paclitaxel Bevacizumab + Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin Bintrafusp alfa + Carboplatin + Paclitaxel | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) | Completed | USA | ESP | 1 |
NCT04630353 | Phase I | HB-201 | A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | Recruiting | USA | 0 |
NCT04652076 | Phase Ib/II | Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) | Recruiting | FRA | 0 |
NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 18 |
NCT04943627 | Phase III | Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine | Balstilimab in Patients With Recurrent Cervical Cancer. | Withdrawn | USA | 1 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Recruiting | USA | 0 |
NCT05475171 | Phase II | MGD019 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Recruiting | USA | 0 |
NCT05521997 | Phase II | Cisplatin + Telaglenastat Cisplatin | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Not yet recruiting | USA | 0 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06079671 | Phase III | MEDI5752 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) | Recruiting | USA | ESP | CAN | 8 |